Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PHARMACEUTICALS

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

CABAZITAXEL IMPURITY FP-A CRS(10 MG)

CABAZITAXEL IMPURITY FP-A CRS(10 MG)

ND

DISCOVER
TEMAZEPAM FOR SYSTEM SUITABILITY CRS - * PSY (1.005 MG)

TEMAZEPAM FOR SYSTEM SUITABILITY CRS - * PSY (1.005 MG)

ND

DISCOVER
ETONOGESTREL IMPURITY MIXTURECRS (100 µL)

ETONOGESTREL IMPURITY MIXTURECRS (100 µL)

ND

DISCOVER
TEMAZEPAM FOR ID AND ASSAY CRS - * PSY (60 MG)

TEMAZEPAM FOR ID AND ASSAY CRS - * PSY (60 MG)

ND

DISCOVER
HYPROMELLOSE ACETATE SUCCINATE CRS (15 MG)

HYPROMELLOSE ACETATE SUCCINATE CRS (15 MG)

ND

DISCOVER
PLATINUM SOLUTION CRS (10 ML)

PLATINUM SOLUTION CRS (10 ML)

ND

DISCOVER
SESTAMIBI LABELLING KIT A CRS(22 MG)

SESTAMIBI LABELLING KIT A CRS(22 MG)

ND

DISCOVER
MEFLOQUINE FOR SYSTEM SUITABILITY CRS (15 MG)

MEFLOQUINE FOR SYSTEM SUITABILITY CRS (15 MG)

ND

DISCOVER
CANNABIDIOL FOR CANNABIS CRS (50 MG)

CANNABIDIOL FOR CANNABIS CRS (50 MG)

ND

DISCOVER
SALIDROSIDE CRS (25 MG)

SALIDROSIDE CRS (25 MG)

ND

DISCOVER
LERCANIDIPINE HYDROCHLORIDE CRS (90 MG)

LERCANIDIPINE HYDROCHLORIDE CRS (90 MG)

ND

DISCOVER
ROSAVIN CRS (25 MG)

ROSAVIN CRS (25 MG)

ND

DISCOVER